Syros Pharmaceuticals, Inc. (SYRS) Covered Calls
There are no covered calls available for Syros Pharmaceuticals, Inc..
Born To Sell's covered call screener gives you full search capabilities so you can find stocks and ETFs that make good covered call candidates.
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts
| Top 10 Open Interest For Sep 19 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | EEM covered calls | 1. | CBRL covered calls | |
| 2. | SPY covered calls | 7. | IBIT covered calls | 2. | AEVA covered calls | |
| 3. | PCG covered calls | 8. | IWM covered calls | 3. | OPEN covered calls | |
| 4. | TSLA covered calls | 9. | SLV covered calls | 4. | QURE covered calls | |
| 5. | QQQ covered calls | 10. | FXI covered calls | 5. | LDI covered calls | |
Want more examples? SYPR Covered Calls | SYY Covered Calls
